In the Journal of the National Cancer Institute this week, researchers in the US and France analyze four prospective cohort studies to determine the association between prediagnostic plasma immunoglobulin E levels and the risk of adult glioma. Increased levels of serum IgE have been inversely associated with risk of glioma, the authors write. For this study, the team combined data from four previous studies and analyzed IgE levels of 169 glioma patients and 520 controls. They found that borderline elevated total IgE levels had a statistically significant inverse association with glioma. However, they found no association between elevated IgE and glioma compared with clinically normal IgE levels. "Overall, our prospective findings are consistent with recent retrospective studies and support an association between total IgE levels and glioma. However, this association requires further elucidation," the authors write.
Also in the Journal of the National Cancer Institute this week, researchers in the US and Puerto Rico report a novel mechanism for tumor cell death in ovarian cancer. The team assessed the expression of the cell signaling molecule p130cas in 91 ovarian cancer specimens, and the effects of p130cas gene silencing alone and in combination with docetaxel. Of the 91 specimens, 76 percent had high expression of p130cas, which was associated with advanced tumor stage and higher residual disease following surgery. High levels of the molecule were also inversely associated with overall survival and progression-free survival, the team observed. In a mouse model of ovarian cancer, silencing p130cas in combination with docetaxel chemotherapy resulted in reduction of tumor growth and increased tumor cells apoptosis. "Increased p130cas expression is associated with poor clinical outcome in human ovarian carcinoma, and p130cas gene silencing decreases tumor growth through stimulation of apoptotic and autophagic cell death," the team writes.
And finally in the Journal of the National Cancer Institute this week, researchers in Boston and Detroit present a study on the predictors and outcomes of limited resection for the treatment of early non-small-cell lung cancer. The team analyzed data from 670 patients diagnosed with stage I lung cancer between 2003 and 2005 — 155 patients underwent limited resection while 524 underwent lobectomy. The team found evidence to suggest that lobectomy is associated with increased long-term survival compared with limited resection, and that "clinical, socioeconomic, and surgeon factors appear to be associated with the choice of surgical resection."